Febrile neutropenia treatment
Reading File
Finding Sources
Searching PubMed
"febrile neutropenia" AND treatment
Reading File
Reading File
Reading File
Reading File
Reading File
I now have comprehensive content from three major textbooks. Let me compile the full answer.
Febrile Neutropenia: Treatment
Definition
- Fever: single oral temperature ≥38.3°C (101°F), or ≥38.0°C (100.4°F) sustained for >1 hour
- Neutropenia: ANC <1000/mm³; severe <500/mm³; profound <100/mm³
Most commonly caused by chemotherapy, with nadir typically 5-10 days after the last dose.
Step 1 - Risk Stratification
Before choosing inpatient vs. outpatient treatment, classify risk using the MASCC Risk Index (available at mascc.org):
High-risk features (hospitalize with IV antibiotics):
- Profound neutropenia expected to last >7-10 days
- Inpatient at time of fever onset
- Hemodynamic instability / septic shock
- Acute leukemia or uncontrolled cancer
- Evidence of organ failure (renal, hepatic)
- Pneumonia, severe soft tissue infection, or central line infection
- Abdominal pain, neurologic changes, severe mucositis
Low-risk features (consider outpatient oral therapy):
- Neutropenia expected to resolve within 7 days
- No comorbid medical conditions
- Well-appearing, no peritoneal signs, normal CXR
- Low MASCC score
Step 2 - Initial Evaluation (within 60 minutes)
- Two blood cultures: one from each lumen of central venous catheter + one peripheral site (or two peripheral sites if no CVC)
- CBC, electrolytes, renal/hepatic function, serum lactate
- Urinalysis + urine culture
- Chest radiograph (note: poorly sensitive for infiltrates in neutropenia)
- Additional cultures (sputum, stool, wound) if clinically indicated
- CT chest/abdomen/pelvis if no source identified on routine workup
- Influenza PCR (in season) - rapid antigen test has insufficient sensitivity
- Consider C. difficile testing if diarrhea present
- Careful physical exam: mouth, sinuses, lungs, skin, perineum/anus, nail beds, all catheter sites. Avoid digital rectal exam until after first antibiotic dose
Step 3 - Empiric Antibiotic Therapy
Start within 60 minutes of presentation. No specific regimen has proven consistently superior; monotherapy is as effective as dual therapy in most cases.
Inpatient - Monotherapy (first-line)
| Agent | Dose |
|---|---|
| Piperacillin/tazobactam | 4.5 g IV q6h |
| Cefepime | 2 g IV q8h |
| Ceftazidime | 2 g IV q8h |
| Imipenem/cilastatin | 1 g IV q8h |
| Meropenem | 1 g IV q8h |
- Use pip/tazo, cefepime, or ceftazidime if no known MDR colonization
- Use imipenem or meropenem if known ESBL-producing organism colonization
- Pseudomonas coverage must always be included
When to Add Vancomycin (not routine)
Vancomycin is not routinely recommended for all febrile neutropenic patients due to the risk of VRE emergence. Add it for:
- Hemodynamic instability / septic shock
- Catheter-related infection with hypotension
- Skin or soft tissue infection (cellulitis)
- Known MRSA or penicillin-resistant pneumococcal colonization
- Positive blood culture for gram-positive organisms (before final ID/sensitivities)
- Severe mucositis with prior fluoroquinolone prophylaxis
- Institutions with high prevalence of MRSA, VSE, or S. mitis
Penicillin Allergy
- Minor allergy: Cefepime, meropenem, or imipenem/cilastatin can usually be given safely
- Severe/anaphylactic allergy: Aztreonam + vancomycin. Avoid empiric fluoroquinolones for gram-negative coverage in this setting
Source-Directed Additions
| Suspected Source | Add |
|---|---|
| Community-acquired pneumonia | Atypical coverage (azithromycin or fluoroquinolone) |
| Suspected Pneumocystis | Trimethoprim-sulfamethoxazole |
| Perianal, oral, or abdominal infection (typhlitis) | Metronidazole or clindamycin (if cefepime used, which lacks anaerobic coverage) |
| Herpes simplex or VZV (ulcerative/vesicular lesions) | Acyclovir |
| Influenza (clinical suspicion) | Oseltamivir empirically if PCR unavailable |
Outpatient (low-risk patients only)
Ciprofloxacin 500 mg PO q12h or Levofloxacin 750 mg PO daily, plus amoxicillin/clavulanate 500/125 mg PO q8h (or clindamycin 300 mg q8h for penicillin allergy). Requires daily reassessment by a medical provider for the first 3 days.
Step 4 - Antifungal Therapy
Up to one-third of febrile neutropenic patients who fail to respond after 7 days of antibiotics have systemic fungal infections (usually Candida or Aspergillus).
- Amphotericin B (or lipid formulations) is the drug of choice for invasive fungal infections
- Micafungin or voriconazole may be used for specific fungal pathogens (preferred when amphotericin toxicity is a concern)
Step 5 - Duration of Therapy
- Median fever duration after starting antibiotics: ~2 days (low-risk) vs. 5-7 days (high-risk)
- Reassess at 2-4 days before changing regimen (earlier if clinical deterioration or culture results)
- Continue antibiotics until:
- Documented infection has clinically resolved AND
- Patient has been afebrile for ≥2 days AND
- ANC has recovered to >500/mm³
Step 6 - Antibiotic De-escalation
A 2025 meta-analysis (PMID 40079575) in Antimicrobial Agents and Chemotherapy found that early antibiotic de-escalation in febrile neutropenia for patients with hematologic malignancy is safe and does not increase mortality - supporting de-escalation once cultures and clinical response are available.
Special Populations
Children with cancer and febrile neutropenia: Principles are similar. Risk stratification is mandatory before deciding inpatient vs. outpatient. Consult the MASCC pediatric criteria; clinical judgment and oncologist guidance are especially important.
Septic patient: Rapid IV fluids and maintain MAP ≥65 mmHg as immediate priority before antibiotic workup is complete.
Sources: Tintinalli's Emergency Medicine, p. 1559; Rosen's Emergency Medicine, p. 3478; Goldman-Cecil Medicine, p. 3132
This is a shared conversation. Sign in to Orris to start your own chat.